{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:42:12Z","timestamp":1792701732909,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,2,27]],"date-time":"2016-02-27T00:00:00Z","timestamp":1456531200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s11910-016-0637-6","type":"journal-article","created":{"date-parts":[[2016,2,27]],"date-time":"2016-02-27T05:42:32Z","timestamp":1456551752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Vaccines in Multiple Sclerosis"],"prefix":"10.1007","volume":"16","author":[{"given":"Eric M. L.","family":"Williamson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Chahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,27]]},"reference":[{"issue":"7","key":"637_CR1","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1177\/1352458510369146","volume":"16","author":"A Langer-Gould","year":"2010","unstructured":"Langer-Gould A, Albers KB, Van Den Eeden SK, Nelson LM. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult Scler. 2010;16(7):855\u201361. Recent review of a large health system\u2019s records that failed to reveal any causal association between vaccination and multiple sclerosis or CNS demyelinating disease, further adding credence to 2011 Institute of Medicine Report.","journal-title":"Mult Scler"},{"issue":"8","key":"637_CR2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archneur.1982.00510200046008","volume":"39","author":"P Dore-Duffy","year":"1982","unstructured":"Dore-Duffy P, Donaldson JO, Rothman BL, Zurier RB. Antinuclear antibodies in multiple sclerosis. Arch Neurol. 1982;39(8):504\u20136.","journal-title":"Arch Neurol"},{"issue":"6","key":"637_CR3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0165-2478(82)90059-1","volume":"4","author":"VK Singh","year":"1982","unstructured":"Singh VK. Detection of antinuclear antibody in the serum of patients with multiple sclerosis. Immunol Lett. 1982;4(6):317\u20139.","journal-title":"Immunol Lett"},{"issue":"3","key":"637_CR4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/jaut.2000.0367","volume":"14","author":"V Roussel","year":"2000","unstructured":"Roussel V, Yi F, Jauberteau MO, Couderq C, Lacombe C, Michelet V, et al. Prevalence and clinical significance of anti-phospholipid antibodies in multiple sclerosis: a study of 89 patients. J Autoimmun. 2000;14(3):259\u201365.","journal-title":"J Autoimmun"},{"issue":"8","key":"637_CR5","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1212\/WNL.31.8.1036","volume":"31","author":"J Mourik","year":"1981","unstructured":"Mourik J, The TH, Nater JP, Minderhoud JM. Cell-mediated immune reactivity in multiple sclerosis. Neurology. 1981;31(8):1036\u20138.","journal-title":"Neurology"},{"issue":"3","key":"637_CR6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40263-015-0226-2","volume":"29","author":"EM Williamson","year":"2015","unstructured":"Williamson EM, Berger JR. Infection risk in patients on multiple sclerosis therapeutics. CNS Drugs. 2015;29(3):229\u201344. Comprehensive review of infections encountered in multiple sclerosis to date, including understanding of how infection may worsen the disease.","journal-title":"CNS Drugs"},{"issue":"12","key":"637_CR7","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1212\/WNL.59.12.1837","volume":"59","author":"OT Rutschmann","year":"2002","unstructured":"Rutschmann OT, McCrory DC, Matchar DB, Immunization Panel of the Multiple Sclerosis Council for Clinical Practice Guidelines. Immunization and MS: a summary of published evidence and recommendations. Neurology. 2002;59(12):1837\u201343.","journal-title":"Neurology"},{"issue":"4","key":"637_CR8","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/01.wnl.0000233834.09743.3b","volume":"67","author":"J Correale","year":"2006","unstructured":"Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology. 2006;67(4):652\u20139.","journal-title":"Neurology"},{"issue":"Pt 5","key":"637_CR9","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/brain\/awf098","volume":"125","author":"D Buljevac","year":"2002","unstructured":"Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain. 2002;125(Pt 5):952\u201360.","journal-title":"Brain"},{"issue":"3","key":"637_CR10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrneurol.2012.8","volume":"8","author":"M Loebermann","year":"2011","unstructured":"Loebermann M, Winkelmann A, Hartung HP, Hengel H, Reisinger EC, Zettl UK. Vaccination against infection in patients with multiple sclerosis. Nat Rev Neurol. 2011;8(3):143\u201351. Another review of vaccinations use in MS, highlights the concern of using live vaccines in concert with immune suppressing agents.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"637_CR11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/1352458508096868","volume":"15","author":"I Sutton","year":"2009","unstructured":"Sutton I, Lahoria R, Tan I, Clouston P, Barnett M. CNS demyelination and quadrivalent HPV vaccination. Mult Scler. 2009;15(1):116\u20139.","journal-title":"Mult Scler"},{"issue":"7","key":"637_CR12","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.autrev.2014.01.054","volume":"13","author":"P Pellegrino","year":"2014","unstructured":"Pellegrino P, Carnovale C, Pozzi M, Antoniazzi S, Perrone V, Salvati D, et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev. 2014;13(7):736\u201341.","journal-title":"Autoimmun Rev"},{"issue":"10","key":"637_CR13","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/archneurol.2011.131","volume":"68","author":"MF Farez","year":"2011","unstructured":"Farez MF, Correale J. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol. 2011;68(10):1267\u201371.","journal-title":"Arch Neurol"},{"key":"637_CR14","volume-title":"Adverse effects of vaccines: evidence and causality","author":"Medicine). IIo","year":"2012","unstructured":"Medicine). IIo. Adverse effects of vaccines: evidence and causality. Washington, DC: The National Academies Press; 2012."},{"issue":"12","key":"637_CR15","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jamaneurol.2014.2633","volume":"71","author":"A Langer-Gould","year":"2014","unstructured":"Langer-Gould A, Qian L, Tartof SY, Brara SM, Jacobsen SJ, Beaber BE, et al. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol. 2014;71(12):1506\u201313.","journal-title":"JAMA Neurol"},{"issue":"5","key":"637_CR16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM200102013440501","volume":"344","author":"C Confavreux","year":"2001","unstructured":"Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S, Vaccines in Multiple Sclerosis Study Group. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med. 2001;344(5):319\u201326.","journal-title":"N Engl J Med"},{"issue":"5","key":"637_CR17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF02962261","volume":"26","author":"J Keyser De","year":"1998","unstructured":"De Keyser J. Safety of tetanus vaccination in relapsing-remitting multiple sclerosis. Infection. 1998;26(5):319.","journal-title":"Infection"},{"issue":"2","key":"637_CR18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1212\/01.wnl.0000225079.51201.f9","volume":"67","author":"MA Hernan","year":"2006","unstructured":"Hernan MA, Alonso A, Hernandez-Diaz S. Tetanus vaccination and risk of multiple sclerosis: a systematic review. Neurology. 2006;67(2):212\u20135.","journal-title":"Neurology"},{"key":"637_CR19","unstructured":"Society NMS. Living Well With MS. Available from: http:\/\/www.nationalmssociety.org\/Living-Well-With-MS ."},{"issue":"37","key":"637_CR20","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1016\/j.vaccine.2014.06.068","volume":"32","author":"P Pellegrino","year":"2014","unstructured":"Pellegrino P, Carnovale C, Perrone V, Pozzi M, Antoniazzi S, Radice S, et al. Efficacy of vaccination against influenza in patients with multiple sclerosis: the role of concomitant therapies. Vaccine. 2014;32(37):4730\u20135. Excellent discussion of the flu vaccine and illustration of the rationale for administering influenza vaccine in patients with MS.","journal-title":"Vaccine"},{"issue":"1","key":"637_CR21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0022-510X(98)00139-7","volume":"159","author":"J Keyser De","year":"1998","unstructured":"De Keyser J, Zwanikken C, Boon M. Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci. 1998;159(1):51\u20133.","journal-title":"J Neurol Sci"},{"issue":"3","key":"637_CR22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF00936886","volume":"242","author":"M Salvetti","year":"1995","unstructured":"Salvetti M, Pisani A, Bastianello S, Millefiorini E, Buttinelli C, Pozzilli C. Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination. J Neurol. 1995;242(3):143\u20136.","journal-title":"J Neurol"},{"issue":"5","key":"637_CR23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000117358","volume":"30","author":"B Michielsens","year":"1990","unstructured":"Michielsens B, Wilms G, Marchal G, Carton H. Serial magnetic resonance imaging studies with paramagnetic contrast medium: assessment of disease activity in patients with multiple sclerosis before and after influenza vaccination. Eur Neurol. 1990;30(5):258\u20139.","journal-title":"Eur Neurol"},{"issue":"2","key":"637_CR24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1212\/WNL.48.2.312","volume":"48","author":"AE Miller","year":"1997","unstructured":"Miller AE, Morgante LA, Buchwald LY, Nutile SM, Coyle PK, Krupp LB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology. 1997;48(2):312\u20134.","journal-title":"Neurology"},{"issue":"49","key":"637_CR25","doi-asserted-by":"crossref","first-page":"9159","DOI":"10.1016\/j.vaccine.2011.08.008","volume":"29","author":"B Michiels","year":"2011","unstructured":"Michiels B, Govaerts F, Remmen R, Vermeire E, Coenen S. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine. 2011;29(49):9159\u201370.","journal-title":"Vaccine"},{"issue":"8","key":"637_CR26","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/1352458513513970","volume":"20","author":"HK Olberg","year":"2014","unstructured":"Olberg HK, Cox RJ, Nostbakken JK, Aarseth JH, Vedeler CA, Myhr K-M. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. Multiple Sclerosis J. 2014;20(8):1074\u201380.","journal-title":"Multiple Sclerosis J"},{"issue":"11","key":"637_CR27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078532","volume":"8","author":"M Mehling","year":"2013","unstructured":"Mehling M, Fritz S, Hafner P, Eichin D, Yonekawa T, Klimkait T, et al. Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFN\u03b2-therapy. PLoS ONE. 2013;8(11), e78532.","journal-title":"PLoS ONE"},{"issue":"12","key":"637_CR28","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1212\/01.wnl.0000188901.12700.e0","volume":"65","author":"SR Schwid","year":"2005","unstructured":"Schwid SR, Decker MD, Lopez-Bresnahan M, Rebif-Influenza Vaccine Study Investigators. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Neurology. 2005;65(12):1964\u20136.","journal-title":"Neurology"},{"issue":"7","key":"637_CR29","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1179\/1743132812Y.0000000059","volume":"34","author":"M V\u00e5gberg","year":"2012","unstructured":"V\u00e5gberg M, Kumlin U, Svenningsson A. Humoral immune response to influenza vaccine in natalizumab-treated MS patients. Neurol Res. 2012;34(7):730\u20133.","journal-title":"Neurol Res"},{"issue":"2","key":"637_CR30","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.22352","volume":"69","author":"M Mehling","year":"2011","unstructured":"Mehling M, Hilbert P, Fritz S, Durovic B, Eichin D, Gasser O, et al. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol. 2011;69(2):408\u201313.","journal-title":"Ann Neurol"},{"issue":"12","key":"637_CR31","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1177\/0091270011427908","volume":"52","author":"C Boulton","year":"2012","unstructured":"Boulton C, Meiser K, David OJ, Schmouder R. Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study. Int J Clin Pharmacol. 2012;52(12):1879\u201390.","journal-title":"Int J Clin Pharmacol"},{"issue":"9","key":"637_CR32","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0000000000001302","volume":"84","author":"L Kappos","year":"2015","unstructured":"Kappos L, Mehling M, Arroyo R, Izquierdo G, Selmaj K, Curovic-Perisic V, et al. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology. 2015;84(9):872\u20139.","journal-title":"Neurology"},{"issue":"6","key":"637_CR33","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1212\/WNL.0b013e31829e6fbf","volume":"81","author":"A Bar-Or","year":"2013","unstructured":"Bar-Or A, Freedman MS, Kremenchutzky M, Menguy-Vacheron F, Bauer D, Jodl S, et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology. 2013;81(6):552\u20138.","journal-title":"Neurology"},{"issue":"1","key":"637_CR34","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.imlet.2015.03.004","volume":"165","author":"R Mormile","year":"2015","unstructured":"Mormile R. Hepatitis B, virus (HBV) infection and multiple sclerosis: one more reason to undergo vaccination? Immunol Lett. 2015;165(1):60\u20131.","journal-title":"Immunol Lett"},{"issue":"8","key":"637_CR35","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s00415-012-6716-y","volume":"260","author":"V Mart\u00ednez-Sern\u00e1ndez","year":"2013","unstructured":"Mart\u00ednez-Sern\u00e1ndez V, Figueiras A. Central nervous system demyelinating diseases and recombinant hepatitis B vaccination: a critical systematic review of scientific production. J Neurol. 2013;260(8):1951\u20139.","journal-title":"J Neurol"},{"issue":"4","key":"637_CR36","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/joim.12155","volume":"275","author":"L Grimaldi-Bensouda","year":"2014","unstructured":"Grimaldi-Bensouda L, Guillemot D, Godeau B, B\u00e9nichou J, Lebrun-Frenay C, Papeix C, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med. 2014;275(4):398\u2013408.","journal-title":"J Intern Med"},{"issue":"1","key":"637_CR37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jama.2014.16946","volume":"313","author":"N Scheller","year":"2015","unstructured":"Scheller N, Svanstr\u00f6m H, Pasternak B, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA. 2015;313(1):54\u201361.","journal-title":"JAMA"},{"issue":"4","key":"637_CR38","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archneur.60.4.504","volume":"60","author":"F DeStefano","year":"2003","unstructured":"DeStefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol. 2003;60(4):504\u20139.","journal-title":"Arch Neurol"},{"issue":"1\u20132","key":"637_CR39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jns.2014.03.035","volume":"341","author":"M Kaufman","year":"2014","unstructured":"Kaufman M, Pardo G, Rossman H, Sweetser MT, Forrestal F, Duda P. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2014;341(1\u20132):22\u20137.","journal-title":"J Neurol Sci"},{"issue":"10","key":"637_CR40","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0b013e3182a35215","volume":"81","author":"CL McCarthy","year":"2013","unstructured":"McCarthy CL, Tuohy O, Compston DA, Kumararatne DS, Coles AJ, Jones JL. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 2013;81(10):872\u20136.","journal-title":"Neurology"},{"issue":"5","key":"637_CR41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1600-0404.2008.01131.x","volume":"119","author":"C Ahlgren","year":"2009","unstructured":"Ahlgren C, Od\u00e9n A, Tor\u00e9n K, Andersen O. Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations. Acta Neurol Scand. 2009;119(5):313\u201320.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"637_CR42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0895-4356(96)00300-9","volume":"50","author":"RT Ross","year":"1997","unstructured":"Ross RT, Nicolle LE, Cheang M. The varicella zoster virus: a pilot trial of a potential therapeutic agent in multiple sclerosis. J Clin Epidemiol. 1997;50(1):63\u20138.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"637_CR43","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00415-011-5984-2","volume":"258","author":"MF Farez","year":"2011","unstructured":"Farez MF, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol. 2011;258(7):1197\u2013206.","journal-title":"J Neurol"},{"issue":"7","key":"637_CR44","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1212\/WNL.53.7.1588","volume":"53","author":"G Ristori","year":"1999","unstructured":"Ristori G, Buzzi MG, Sabatini U, Giugni E, Bastianello S, Viselli F, et al. Use of Bacille Calmette-Guerin (BCG) in multiple sclerosis. Neurology. 1999;53(7):1588\u20139.","journal-title":"Neurology"},{"issue":"1","key":"637_CR45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1212\/01.wnl.0000438216.93319.ab","volume":"82","author":"G Ristori","year":"2014","unstructured":"Ristori G, Romano S, Cannoni S, Visconti A, Tinelli E, Mendozzi L, et al. Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS. Neurology. 2014;82(1):41\u20138.","journal-title":"Neurology"},{"issue":"2","key":"637_CR46","volume":"2","author":"A Bar-Or","year":"2015","unstructured":"Bar-Or A, Wiendl H, Miller B, Benamor M, Truffinet P, Church M, et al. Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens. Neurol Neurophysiol Neurosci. 2015;2(2), e70.","journal-title":"Neurol Neurophysiol Neurosci"},{"issue":"4","key":"637_CR47","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/cns.12067","volume":"19","author":"YD Fragoso","year":"2013","unstructured":"Fragoso YD, Brooks JB, Gomes S, de Oliveira FT, da Gama PD. Report of three cases of herpes zoster during treatment with natalizumab. CNS Neurosci Ther. 2013;19(4):280\u20131.","journal-title":"CNS Neurosci Ther"},{"issue":"19","key":"637_CR48","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1212\/WNL.0b013e3182735edf","volume":"79","author":"D Bourdette","year":"2012","unstructured":"Bourdette D, Gilden D. Fingolimod and multiple sclerosis: four cautionary tales. Neurology. 2012;79(19):1942\u20133.","journal-title":"Neurology"},{"issue":"22","key":"637_CR49","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1212\/01.wnl.0000439052.05262.1d","volume":"81","author":"B Bourre","year":"2013","unstructured":"Bourre B, Lefaucheur R, Ahtoy P, Travers F, Fetter D. Varicella zoster virus acute myelitis in a patient with MS treated with natalizumab. Neurology. 2013;81(22):1966\u20137.","journal-title":"Neurology"},{"issue":"19","key":"637_CR50","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1212\/WNL.0b013e3182918d27","volume":"80","author":"J Yeung","year":"2013","unstructured":"Yeung J, Cauquil C, Saliou G, Nasser G, Rostomashvili S, Adams D, et al. Varicella zoster virus acute myelitis in a patient with MS treated with natalizumab. Neurology. 2013;80(19):1812\u20133.","journal-title":"Neurology"},{"key":"637_CR51","unstructured":"Novartis. Gilenya [package insert]. Stein SDbNPCEH, New Jersey. Revised August 2015."},{"key":"637_CR52","unstructured":"Genzyme. Lemtrada [package insert]. Cambridge MG, 2015."},{"key":"637_CR53","unstructured":"Merck. Varivax PI. Merck."},{"issue":"4","key":"637_CR54","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.msard.2013.03.002","volume":"2","author":"JR Berger","year":"2013","unstructured":"Berger JR. Varicella vaccination after fingolimod: a case report. Mult Scler Relat Disord. 2013;2(4):391\u20134.","journal-title":"Mult Scler Relat Disord"},{"key":"637_CR55","unstructured":"Genzyme. Aubagio prescribing information. Cambridge MG, 2015."},{"key":"637_CR56","doi-asserted-by":"crossref","unstructured":"Chahin S, Berger JR. A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy. J Neurovirol. 2014.","DOI":"10.1007\/s13365-014-0303-1"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-016-0637-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-016-0637-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-016-0637-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T02:10:42Z","timestamp":1567649442000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-016-0637-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,27]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["637"],"URL":"https:\/\/doi.org\/10.1007\/s11910-016-0637-6","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,27]]},"article-number":"36"}}